[Nosebleed in new oral anticoagulant treatment - what should be done?].
, .
Peter
P
Stiefelhagen
D000284:Administration, Oral; D000368:Aged; D000991:Antithrombins / Q000008:administration & dosage / Q000009:adverse effects*; D001281:Atrial Fibrillation / Q000188:drug therapy; D000069604:Dabigatran / Q000008:administration & dosage / Q000009:adverse effects*; D004334:Drug Administration Schedule; D057915:Drug Substitution; D004844:Epistaxis / Q000139:chemically induced*; D065427:Factor Xa Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D000069552:Rivaroxaban / Q000008:administration & dosage / Q000009:adverse effects*
D000991:Antithrombins; D065427:Factor Xa Inhibitors; D000069552:Rivaroxaban; D000069604:Dabigatran